Business Context and Reporting Period
Company: ILLUMINA, INC. (ILMN)
Filing Type: Form 10-Q
Reporting Period: Fiscal Quarter Ended March 29, 2026 (Q1 2026)
Business Overview: Illumina is a global leader in DNA sequencing and array-based technologies serving research, clinical, and applied markets. In Q1 2026, the company acquired SomaLogic, a proteomics company, to advance its multiomics strategy. The company operates as a single reportable segment.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $1,091 million | $1,041 million |
| Gross Profit | $721 million | $683 million |
| Gross Margin | 66.1% | 65.6% |
| Operating Income | $209 million | $164 million |
| Operating Margin | 19.2% | 15.8% |
| Net Income | $134 million | $131 million |
| Diluted EPS | $0.87 | $0.82 |
| Operating Cash Flow | $289 million | $240 million |
| Cash & Short-term Investments | $1,155 million | $1,633 million (implied) |
| Total Debt (Principal) | $2,000 million | $2,000 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 5% year-over-year, driven by a 4% increase in product revenue (sequencing consumables and instruments) and an 8% increase in service revenue, partially attributable to the SomaLogic acquisition.
- Profitability Expansion: Operating income rose $45 million (27%) due to a $38 million increase in gross profit and a $7 million decrease in operating expenses. The reduction in operating expenses was primarily driven by a $28 million decrease in restructuring charges compared to Q1 2025.
- Acquisition Impact: On January 30, 2026, Illumina acquired SomaLogic for a total purchase price of $460 million ($382 million cash + $81 million contingent consideration). This added $171 million to goodwill and $186 million to intangible assets.
- Tax Rate Variance: The effective tax rate decreased significantly to 14.8% from 27.9% in the prior year, primarily due to prior year tax return adjustments and a favorable mix of earnings in lower-tax jurisdictions.
- Investment Losses: "Other (expense) income, net" swung from a $32 million gain in Q1 2025 to a $39 million expense in Q1 2026, largely due to net losses on strategic investments (including the retained GRAIL stake).
Guidance, Outlook, Risks, and Unusual Items
- Outlook & Strategy: Management continues to pursue strategic goals for revenue growth and margin improvement by the end of 2027. The company expects to fully mitigate tariff impacts in 2026 through supply chain optimization and pricing actions.
- Tariff & Geopolitical Risks: The company faces headwinds from U.S. tariffs (specifically on imports from Singapore), inflation, and geopolitical instability in the Middle East and Ukraine, which may increase freight and energy costs. Illumina is seeking refunds for IEEPA-related tariffs, though timing and amounts are uncertain.
- China Exposure: Revenue in Greater China decreased $20 million year-over-year due to the company's inclusion on China's "unreliable entities list."
- Legal Proceedings: Significant ongoing litigation includes shareholder derivative suits and securities class actions related to the 2020 acquisition of GRAIL. While one derivative action (Icahn Partners) reached a settlement in principle with no payment, other consolidated actions remain pending with motions to dismiss filed.
- Share Repurchases: The Board authorized a new $1.5 billion repurchase program in April 2026, in addition to the remaining authorization under the 2024 program. The company repurchased approximately $243 million of stock in Q1 2026.
Investor Verification Checklist
- SomaLogic Integration: Verify the timeline for realizing synergies and the specific revenue contribution of SomaLogic in subsequent quarters.
- Tariff Refund Status: Monitor updates on the U.S. Customs and Border Protection (CBP) administrative refund process for IEEPA-related tariffs to assess potential cash flow recoveries.
- China Revenue Trajectory: Track the impact of the "unreliable entities list" designation on Greater China revenue and potential market share loss.
- GRAIL Litigation Resolution: Follow the status of the consolidated securities class actions and derivative suits regarding the GRAIL acquisition to assess potential liability or distraction.
- Debt Maturity Profile: Note the $500 million 2026 Term Notes maturing in September 2026 and the company's liquidity position relative to this obligation.